# A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

> **NCT06015503** · PHASE2 · RECRUITING · sponsor: **Avistone Biotechnology Co., Ltd.** · enrollment: 157 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** PLB1004

## Key facts

- **NCT ID:** NCT06015503
- **Lead sponsor:** Avistone Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-21
- **Primary completion:** 2025-03-06
- **Final completion:** 2025-10-30
- **Target enrollment:** 157 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015503, "A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06015503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*